Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
China Background Orelabrutinib is a novel, small molecule, selective irreversible Bruton tyrosine kinase inhibitor, approved in China for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). The previous publication of this study reported that orelabrutinib is highly active in R/R Waldenström’s macroglobulinemia (WM), with a well-tolerated safety prole (EClinicalMedicine. 2022;52:101682). We present here the long-term results of this study. Methods This is a prospective, multicenter study of orelabrutinib in patients with WM who had at least one prior line of treatment (ClinicalTrials NO. : NCT04440059). Orelabrutinib was administered orally at a daily dose of 150 mg until disease progression or unacceptable toxicity.
第一作者单位：[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Cao Xinxin,Jin Jie,Cheng Fu Cheng,et al.Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results[J].BLOOD.2023,142:doi:10.1182/blood-2023-181500.
APA：
Cao, Xinxin,Jin, Jie,Cheng, Fu Cheng,Yi, Shuhua,Zhao, Weili...&Zhou, Daobin.(2023).Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results.BLOOD,142,
MLA：
Cao, Xinxin,et al."Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results".BLOOD 142.(2023)
医学